1. In Vivo
  2. >>Innovation

In Silico Drug Design: Finally Ready For Prime Time?

 
• By Michael Goodman

Advances in computational power and in the application of quantum mechanics to drug modeling are rekindling interest in in silico drug design. The prize is a steep reduction in the cost of discovery and an increase in the quality of lead candidates.

Building on improvements in the price-performance of computing power and on early efforts to incorporate principles of physics in the modeling of ligand/receptor interactions, a few pioneering companies like Nimbus Therapeutics and Verseon Corp. are pushing the boundaries of computational drug design.

Kenneth M. Merz, PhD, director of Michigan State University’s Institute for Cyber-Enabled Research, and former head of Pharmacopeia Inc.’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

IMMA Starts A Silent Revolution By Making IVF Journey Digital, Predictable And At Home

 
• By Ashley Yeo

IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By Ashley Yeo

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

More from In Vivo

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By Ashley Yeo

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.

Rising leaders 2025: Aneesh Karatt-Vellatt On Maxion Therapeutics’ Antibody Revolution

 
• By Jo Shorthouse

Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.